Johnson & Johnson Financials and Guidance Call Transcript
Hello. This is Jessica Moore, Vice President of Investor Relations for Johnson & Johnson. Welcome to the company's review of our updated financials and 2023 guidance as a company dedicated to pharmaceutical and med tech innovation following the completion of the Kenvue exchange offer. I am joined by Joe Wolk, Executive Vice President, Chief Financial Officer. Before we get started, you can find additional materials, including the associated press release, presentation, transcript and supplemental schedules on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com.
Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events using the information available as of the date of this recording and are subject to certain risks and uncertainties that may cause the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |